Navigation Links
Rapid-Acting Antidepressants Reviewed by NeuroPerspective
Date:12/11/2012

CARDIFF, Calif., Dec. 11, 2012 /PRNewswire/ -- NI Research has released the December issue of NeuroPerspective, which features a comprehensive review of pharmacotherapies for depression, with a particular focus upon the programs developing RAADs, rapid-acting antidepressants, an approach that springs from the reports of accelerated depression relief via the use of ketamine.

This 29-page issue includes:
1) An overview of the biology of depression and the implications of accelerated treatment effect for our understanding of depression and pathways for intervention.

2) A review of the many therapeutic strategies that are currently under development, with a special focus upon glutamatergic approaches, those which access the NMDA receptor and associated modulator components. These constitute the pathways for RAADs, where symptom relief may occur in hours, rather than weeks.

Among the programs reviewed, the leaders in the race for a RAAD include:

Naurex, whose Phase IIa data for IV GLYX-13 was just released. In spite of the fact that this was a 116pt dose-ranging study in TRD patients, limited by the small cohort sizes for each of the active treatment groups, GLYX-13 exceeded expectations. Most importantly, none of the doses produced psychotomimetic effects in any patients. The pilot study now requires confirmation from the multiple-dose PhIIb trial underway.

Various Ketamine and Ketamine-combination drugs: These programs are hoping to skirt the risk of psychotomimesis via a variety of tactics. Programs in this vein are underway at JNJ/Addex, Lilly, AstraZeneca, Washington University, Yale, and Mt. Sinai.

AstraZeneca's IV AZD6765 has been tested more extensively than most of its competitors, but it is relatively slow to achieve therapeutic effect, and psychotomimetic concerns are not completely alleviated.

Naurex has an orally bioavailable version of GLYX-13, NRX-1074, approaching IND-readiness. If it emulates GLYX-13's impact and safety, NRX-1074 would widen the scope of Naurex's market across the full range of depression. In terms of other oral glutamatergic options, companies involved in this area include: NeurOp/Bristol Myers Squibb, Lilly, Roche, BrainCells, and Vanderbilt University.

Alkermes' ALKS5461 program has the burden of its opioid legacy, which would almost certainly result in Schedule II placement, and what may be some initial euphoric/intoxicant effects.

Other depression programs of note include:

Vortioxetine, the triple amine reuptake inhibitor from Lundbeck/Takeda, in NDA-preparation, and Euthymics Bioscience with its triple amine drug, amitifadine. Forest/Pierre Fabre's levomilnacipran is having its NDA prepared. Methylation Sciences is developing a reformulation of SAMe that they believe has much better bioavailability. This could be of interest to patients and prescribers who would perceive it as less "drug," more "nutriceutical."

3) Other neurotherapeutic stories of note in the December issue include:

The successful Phase III results for Acadia Pharmaceuticals' pimavanserin.

An illuminating graphic comparison of the six-month efficacy results for EnVivo's EVP-6124 and Lilly's solanezumab.

About NI Research
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective (formerly NeuroInvestment) is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analysis of therapeutics-in-development.

A one-year subscription to NeuroPerspective is $2,300. The December issue of NeuroPerspective is available for $300 as a single-issue purchase.

NI Research also publishes NeuroLicensing, the Private CNS Company Review, and NeuroSynopsis, a monthly four-page summary of highlights from NeuroPerspective. NIR also provides consulting services to the pharma industry regarding licensing and strategic planning.

Further information and online purchasing with immediate delivery are available at http://www.niresearch.com/onlinestore.html


'/>"/>
SOURCE NI Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Peer Reviewed Clinical Study Shows New Blood Test More Accurately Predicts Risk Of A Heart Attack
2. Alzheimers Therapeutics Reviewed by NeuroPerspective
3. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
4. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... YORK , May 26, 2016 ... investors see value in this space. Today,s pre-market research on ... equities: Radius Health Inc. (NASDAQ: RDUS ), Cerus ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... stock technical briefings at: http://www.activewallst.com/ ...
(Date:5/26/2016)... ... 26, 2016 , ... FireflySci has been manufacturing quartz and ... over the globe. Their cute firefly logo has been spreading to more and ... spectrophotometer calibration standards that never require recalibration. These revolutionary standards have changed ...
(Date:5/25/2016)... Oregon (PRWEB) , ... May 25, 2016 , ... ... Set features a variety of fracture-specific plating options designed to address fractures of ... industry-leading fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed ...
(Date:5/25/2016)... ... ... at the University of Athens say they have evidence that the variety of different ... lead to one good one. Surviving Mesothelioma has just posted an article on the ... 98 mesothelioma patients who got a second kind of drug therapy after ...
Breaking Biology Technology:
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
(Date:3/17/2016)... LONDON , March 17, 2016 ... market intelligence, forecasts the global biometrics market will ... an impressive 118% increase from 2015. Consumer electronics, ... with embedded fingerprint sensors anticipated to reach two ... Dimitrios Pavlakis , Research Analyst ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
Breaking Biology News(10 mins):